KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials
50 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
This study is looking at a new drug called Pralsetinib for advanced lung cancer where a specific genetic change (RET fusion) is present. It compares Pralsetinib to standard treatments to see if it works better or has fewer side effects for people who haven't had treatment for this type of cancer before.
For: RET fusion−positive · metastatic Non-Small Cell Lung CancerFrance · Netherlands · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
This study looks at a new drug, erdafitinib, for people with advanced bladder cancer that has a specific gene change. It compares erdafitinib to standard treatments like pembrolizumab, docetaxel, or vinflunine to see if it helps people live longer.
For: Advanced Urothelial CancerFrance · Spain · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS - THE ARETHUSA TRIAL
This study looks at a new way to treat advanced bowel cancer that has spread. It combines existing chemotherapy with an immunotherapy drug, pembrolizumab, hoping to make the immunotherapy more effective for people whose cancer hasn't responded to previous treatments.
For: Metastatic colorectal cancerItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
This study is testing new combinations of medicines for advanced melanoma, a type of skin cancer that has spread or can't be removed by surgery. It looks at how safe the medicines are and how well they shrink tumours.
For: Unresectable or Metastatic MelanomaGermany · Spain - AuthorisedPhase I and Phase II (Integrated)- Bioequivalence Study
PHASE 1B/II TRIAL OF CHECKPOINT INHIBITOR (PEMBROLIZUMAB AND ANTI PD-1 ANTIBODY) PLUS STANDARD IMRT IN HPV INDUCED STAGE III SQUAMOUS CELL CARCINOMA OF ANUS
This study looks at a new way to treat anal cancer caused by HPV. It combines a standard radiation and chemotherapy treatment with a new drug called pembrolizumab (Keytruda). The main goal is to see if this combination treatment is safe and well-tolerated.
For: Anal cancerNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer. It combines standard chemotherapy with newer drugs, pembrolizumab and olaparib, to see if this mix works better than current treatments in slowing down cancer growth and helping people live longer and feel better.
For: Stage IV lung cancer conditionRomania · Austria · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
This study looks at new treatments for head and neck cancer that has come back or spread after previous therapies. It compares a new drug, Lenvatinib, alone or with Pembrolizumab, against standard chemotherapy. We want to see if these new approaches help people live longer and improve their health.
For: Recurrent or metastatic squamous cell carcinoma of the head and neckNorway · Denmark · Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-03)
This study looks at a new treatment called ALX148 combined with an existing cancer drug, pembrolizumab (Keytruda), for advanced head and neck cancer. Researchers want to see if this combination helps shrink tumours or stop them from growing.
For: metastatic or unresectable · recurrent HNSCCNetherlands · Belgium · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer
This study is testing a new medicine, JK08, for people with advanced cancer that can't be removed by surgery. It's looking to find the safest dose of JK08, both on its own and with other existing cancer drugs like Keytruda and Lenvima. This is one of the first times this new medicine is being given to people.
For: Unresectable Locally Advanced or Metastatic CancerSpain · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-04)
This study is testing a new combination of medicines for people with advanced head and neck cancer. It combines an experimental drug called ALX148 with an existing treatment (pembrolizumab) and chemotherapy. Researchers want to see how well this new combination shrinks tumours.
For: metastatic or unresectable · recurrent HNSCCBelgium · Netherlands · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability, and Effects on Tumour Biomarkers of the NOX1/4 Inhibitor Setanaxib, when Administered with the PD-1 Inhibitor Pembrolizumab, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This study is looking at a new drug called Setanaxib combined with an existing cancer treatment (Pembrolizumab) for people with head and neck cancer that has come back or spread. Researchers want to see if this combination can shrink tumours, how safe it is, and if it helps people feel better.
For: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)Spain · Italy · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
This study looks at a new treatment for solid tumours, which are common types of cancer. It uses a patient's own immune cells, called TILs, to fight the cancer. Researchers want to see how well these cells work at shrinking tumours and keeping the cancer away.
For: NeoplasmSpain · Germany · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
This study looks at new treatments for a type of head and neck cancer that has come back or spread. It compares an immunotherapy drug called pembrolizumab, alone or with another drug called epacadostat, against a standard treatment.
For: Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapiesPortugal · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC).
This study looks at a new way to treat advanced bowel cancer that has a specific genetic weakness. It combines two drugs, Pembrolizumab and Olaparib, to see if they can shrink tumours or stop them from growing.
For: Colorectal cancerSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
This study is testing a new medicine called Keytruda for people in the UK with certain types of lymphoma that have come back or not responded to previous treatments. It aims to see how well Keytruda shrinks the lymphoma and if it is safe.
For: Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell LymphomaPoland · Italy · Czechia - AuthorisedTherapeutic exploratory (Phase II)
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)
RESET C2 is a study looking at a new way to treat early colon cancer that has a specific genetic marker (dMMR). It uses an immunotherapy drug (Keytruda) before surgery, aiming to shrink the cancer so surgery might not be needed, or to make it less extensive.
For: Localised dMMR Colon CancerDenmark - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007).
This study is looking at a new treatment for a type of skin cancer called cutaneous squamous cell carcinoma (cSCC). It combines a new vaccine (mRNA-4157) with an existing drug (pembrolizumab) to see if it works better than standard care for people whose cancer can be removed by surgery.
Italy · Czechia · Romania - Ongoing, recruitingTherapeutic exploratory (Phase II)
Calcium electroporation in combination with irreversible electroporation and immunotherapy in patients with pMMR metastatic colorectal cancer - A prospective, phase 2 study
This study is looking at a new way to treat bowel cancer that has spread. It combines special electrical treatments with an immunotherapy drug, pembrolizumab. Researchers want to see if this combination is safe and how well it works together.
For: Colorectal cancerDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
This study looks at a new treatment for advanced melanoma that has not responded to previous immunotherapy. It combines an injected drug (LTX-315) with an existing cancer drug (Pembrolizumab) to see if it can shrink tumours and extend life. Researchers will closely monitor participants' health.
For: Advanced MelanomaFrance · Norway · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
This study is looking at two medicines, pembrolizumab and brentuximab vedotin, for people with Hodgkin lymphoma that has come back or hasn't responded to other treatments. It wants to see which medicine works better at stopping the cancer from growing and helping people live longer.
For: Hodgkin lymphomaSweden · Czechia · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
This study looks at a medicine called Keytruda after surgery for kidney cancer to see if it stops the cancer from coming back. It compares Keytruda to a dummy medicine to find out if it's safe and effective.
For: Renal cell carcinomaNetherlands · Poland · Finland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
This study looks at a new drug, pembrolizumab (Keytruda), combined with another medicine, enzalutamide. It's for men with advanced prostate cancer that has spread and isn't responding to hormone treatment. We want to see if this combination helps men live longer and slows down the cancer's growth.
For: Metastatic Castration-Resistant Prostate CancerAustria · Italy · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
This study is testing a new medicine called Keytruda after surgery and radiation for advanced skin cancer (cutaneous squamous cell carcinoma). We want to see if it stops the cancer from coming back compared to a dummy treatment.
For: Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC)Germany · France · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
This study is looking at a new way to treat early-stage lung cancer that hasn't spread. It combines a type of radiation called SBRT with a drug called Keytruda or a dummy drug to see if it works better and improves how long people live without their cancer getting worse.
For: Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)Germany · Netherlands · Norway - Ongoing, recruitingPhase II and Phase III (Integrated)
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK 009)
This study looks at new treatments for a type of breast cancer called Triple Negative Breast Cancer (TNBC) that has spread or come back. It compares a new drug combination with current treatments to see which works best and improves quality of life.
For: Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)Hungary · Ireland · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
This study looks at a new way to treat an aggressive type of breast cancer called Triple Negative Breast Cancer (TNBC). It combines a special immune-boosting drug (Pembrolizumab) with standard chemotherapy to see if it can shrink tumours more effectively before surgery and prevent them from returning.
For: Triple Negative Breast Cancer (TNBC)Portugal · Germany · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
This study is testing a new cancer medicine, MK-1088, sometimes with an existing medicine called Pembrolizumab (Keytruda). We want to find out if it's safe for people with advanced solid tumours and how well it's tolerated. It's an early-stage study focusing on safety.
For: Treatment of advanced/metastatic solid tumorsDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
This study is looking at a new treatment called Keytruda for people who have had liver cancer removed by surgery or other procedures. It compares Keytruda to a dummy treatment (placebo) to see if it can stop the cancer from coming back and help people live longer.
For: Adjuvant treatment of HCCGermany · Belgium · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008)
This study looks at new treatments for advanced lung cancer that has already been treated. It compares a combination of two drugs (pembrolizumab and lenvatinib) to another drug (docetaxel) to see which is more effective and safer.
For: NSCLC with squamous or nonsquamous histologyFrance · Italy · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)
This study is testing new treatments for a type of advanced ovarian cancer in women. It combines chemotherapy with a new drug called pembrolizumab, followed by another new drug, olaparib, to see if it can keep the cancer from growing for longer. It's for women whose cancer does not have a specific gene change called BRCA.
For: Advanced epithelial ovarian cancerGermany · Czechia · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
This study is looking at new treatments for a type of early bladder cancer that hasn't responded to usual therapy. We are testing medicines like pembrolizumab (Keytruda) alone or with other drugs to see if they can help patients whose cancer is considered high-risk.
For: Non-Muscle Invasive Bladder Cancer (NMIBC)Finland · Greece · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This study looks at a new combination treatment (Vibostolimab with Pembrolizumab) for melanoma skin cancer that has a high chance of coming back. It compares this combination to an existing treatment (Pembrolizumab alone) to see if it can stop the cancer from returning.
For: melanomaAustria · France · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
This study is looking at new ways to treat advanced oesophageal cancer. We're testing a combination of new drugs and chemotherapy to see if it works better than standard treatments, with a focus on safety and how long people live while on the treatment.
For: Esophageal CarcinomaSpain · Hungary · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN1046 in Combination With Anticancer Agents in Subjects With Advanced Endometrial Cancer
This study is looking into a new treatment for advanced endometrial cancer. It combines a new drug, called DuoBody®-PD-L1x4-1BB, with an existing cancer medicine, KEYTRUDA. Doctors want to see if this combination is safe and if it can shrink tumours.
For: Advanced Endometrial CancerItaly · Spain · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
This study is looking at new treatments for advanced liver cancer in people who haven't had treatment before. Researchers want to see how safe the new treatment is and if it can help slow down or shrink the cancer. It combines a new medicine called MK-1308A with an existing drug, Lenvatinib.
For: Hepatocellular carcinomaSpain · Italy · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
This study is looking at a new combination of medicines (Lenvatinib and Pembrolizumab) plus TACE for people with liver cancer that hasn't spread. We want to see if this combination works better than TACE alone to stop the cancer from growing and help people live longer.
For: Incurable/Non-metastatic Hepatocellular CarcinomaGermany · Portugal · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
This study is looking at a new combination of two medicines, Lenvatinib and KEYTRUDA, for adults with a type of kidney cancer called non-clear cell renal cell carcinoma (nccRCC). It’s in an early stage of testing to see how well patients respond to the treatment.
For: Non-clear Cell Renal Cell CarcinomaItaly · Spain · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
This study is looking at a new treatment before and after surgery for certain skin cancers and head and neck cancers. It combines two new drugs (IO102-IO103) with an existing cancer drug (Keytruda) to see how effectively they shrink tumors and improve patient outcomes.
For: Melanoma and squamous cell carcinoma of the head and neckSpain · Germany · Denmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
This study looks at a new treatment called pembrolizumab, combined with standard chemotherapy, for adults recently diagnosed with classical Hodgkin lymphoma. Researchers want to see how many patients go into complete remission at the end of the treatment plan.
For: Classical Hodgkin LymphomaFrance · Poland · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
This study is looking at new ways to treat bladder cancer that has spread or come back. It's testing a new drug, Padcev, on its own or with other key cancer medicines to see how well they work and if they cause side effects.
For: Urothelial cancerFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
This study looks at a new combination of treatments for advanced non-small cell lung cancer. It compares a new drug (MK-7684A) plus chemotherapy to an existing drug (pembrolizumab) plus chemotherapy, to see which works better and is safer.
For: Metastatic Non-Small Cell Lung CancerGermany · Spain · Austria - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies
This study is looking at a new combination of treatments, including a medicine called Keytruda, for people with blood cancers. Doctors want to see how safe this new combination is and if it helps to treat these cancers. It's an early-stage study to learn more about the treatment.
For: Hematologic malignanciesItaly · Germany · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
This study is looking at new treatments for advanced or returning womb cancer. It compares a combination of two anti-cancer drugs (pembrolizumab and lenvatinib) with standard chemotherapy. The aim is to see which treatment works best to stop the cancer from growing and to help people live longer.
For: Participants with advanced or recurrent endometrial carcinomaIreland · Austria · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer (KEYVIBE-003)
This study is looking at a new combination medicine, MK-7684A, compared to an existing treatment, Keytruda, for advanced lung cancer. It aims to see if the new combination can help people live longer when their cancer has a specific marker called PD-L1.
For: Stage IV non small-cell lung cancerRomania · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)
This study is looking at a new combination of medicines for some types of cancer, called MK-4280A and pembrolizumab. It wants to see how well these medicines shrink tumours and if they help people feel better. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
For: Neoplasm malignantFrance · Italy · Netherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
This study is testing a new drug, BI 1910, for people with advanced cancers. It will check how safe the drug is, what side effects it causes, and how much of it the body can handle, both on its own and when given with another cancer drug.
For: Advanced solid tumorsDenmark · Poland · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at a new combination of medicines to treat a serious type of lung cancer. It compares two new drugs called zimberelimab and domvanalimab, given together, against a standard treatment called pembrolizumab, to see if the new combination helps people live longer.
For: Squamous Non-small cell Lung Cancer · Non-Small Cell Lung Cancer · Non squamous Non Small Cell Lung CancerIreland · Spain · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
This study looks at a new drug, pembrolizumab (Keytruda), combined with standard chemotherapy for a type of cancer called biliary tract cancer. It aims to see if this combination helps people live longer compared to chemotherapy alone. It's a large study, comparing the two treatments directly.
For: Biliary Tract CarcinomaIreland · Germany · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab, versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE).
This study looks at new ways to treat a type of liver cancer that has spread. It compares two treatments: one using regorafenib and pembrolizumab given through the body, and another using targeted treatments like TACE or TARE directly in the liver. The main goal is to see which treatment works best to stop the cancer from growing.
For: Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.Belgium · Spain · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
This study is testing a new medicine, ALE.C04, alone and with an existing drug, Pembrolizumab, for head and neck cancer that has come back or spread. It will check if the new medicine is safe and if it can help shrink the cancer.
For: Recurrent or Metastatic (R/M) Head and Neck Squamous Cell CarcinomaItaly · Spain · France